Tokyo, Japan

Yohei Matsueda

This inventor holds 1 USPTO granted patent. Top assignee: Teijin Pharma Limited. Active years: 2008.


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yohei Matsueda: Innovator in Pharmaceutical Chemistry

Introduction

Yohei Matsueda is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on pyrazolo[1,5-a]pyridine derivatives. His research focuses on developing compounds that exhibit valuable therapeutic properties.

Latest Patents

Matsueda holds a patent for pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof. This compound, represented by formula (I), demonstrates excellent MAPKAP-K2 inhibitory activity. Medicines containing this compound as an active ingredient are anticipated to be effective in treating or preventing diseases mediated by MAPKAP-K2, including inflammatory injury, autoimmune diseases, asteropathia destruens, cancer, and tumor growth. He has 1 patent to his name.

Career Highlights

Matsueda is currently employed at Teijin Pharma Limited, where he continues to advance his research in pharmaceutical development. His work has garnered attention for its potential impact on various medical conditions.

Collaborations

Matsueda collaborates with notable colleagues, including Gen Unoki and Yoshiyuki Matsumoto. Their combined expertise contributes to the innovative research environment at Teijin Pharma Limited.

Conclusion

Yohei Matsueda's contributions to pharmaceutical chemistry, particularly through his patented work on pyrazolo[1,5-a]pyridine derivatives, highlight his role as a key innovator in the field. His ongoing research promises to advance the treatment of significant medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…